抄録
Basic research has produced a wealth of knowledge regarding the molecular mechanisms of cancer development, and antineoplastic agents that target specific molecules have been developed. These agents have the potential to revolutionize cancer management in terms of the risk/benefit ratio of treatment. This review article provides general concepts of pharmacokinetics and pharmacodynamics data of molecularly targeted agents, e.g. erlotinib. Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that has been used to treat nonsmall cell lung cancer and pancreatic cancer.
